HONG KONG, Sept. 28, 2026 /PRNewswire/ — Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating cadonilimab, Akeso’s first-in-class PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy versus chemotherapy with or without nivolumab as first-line treatment for patients […]

New digital ecosystem delivers greater customer choice, deeper engagement and a more sustainable travel insurance model Allianz Partners launches the Metaportal to support changing rewards and loyalty programs. Greater customer choice through personalised travel insurance experiences. Scalable technology platform built for future growth and innovation. BRISBANE, Australia, Sept. 28, 2026 /PRNewswire/ — Allianz Partners today […]

SAN FRANCISCO and SUZHOU, China, Sept. 28, 2026 /PRNewswire/ — Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic, and ophthalmic diseases, announces expansion of the global Phase 3 MarsLight-11 (NCT07217301) trial, which is evaluating IBI363 (Takeda R&D code: […]

HONG KONG, Sept. 28, 2026 /PRNewswire/ — Xsight Group (known as Xsight), a Hong Kong–headquartered cross-border technology group founded in 2004, has been featured as a research case in "How AI Agents Orchestrate Work Across Silos," a special report published in the September–October 2026 issue of Harvard Business Review. The article examines how a new […]

SHENZHEN, China, Sept. 26, 2026 /PRNewswire/ — On September 23, the 5th GMIF2026 Innovation Summit successfully concluded at the Renaissance Shenzhen Bay Hotel. Co-hosted by the Shenzhen Memory Industry Association (SMIA) and School of Integrated Circuits at Peking University, the summit, themed "The Future Built on AI Memory and Storage," has brought together industry forces […]

BEIJING, Sept. 27, 2026 /PRNewswire/ — The 2026 Beijing International Week for Science Literacy opened at the Beijing Science Center, running from September 22 to 26. Representatives of international organizations, universities, science museums and centers, and science communication institutions from 11 countries gathered in Beijing. Focusing on science communication and science education, they exchanged views […]

— Late-breaking oral presentation of first-in-human data (LBA-11) showed that a single intravenous infusion of IASO206 generated functional BCMA CAR-T cells in vivo without lymphodepleting chemotherapy. The study demonstrated a 90% objective response rate and a 90% MRD negativity rate in a population in which 90% of patients had high-risk and 70% had ultra-high-risk cytogenetic […]

— In a large China real-world study of 281 heavily pretreated, predominantly high-risk patients with relapsed/refractory plasma cell neoplasms, FUCASO achieved a 95.9% objective response rate, a 77.2% CR/sCR rate, and a 94.1% MRD negativity rate — with median PFS and OS not yet reached (12-month PFS 71.5%, OS 87.8%) and consistent benefit across high-risk […]